LCD L33787

A Local Coverage Determination issued by Medicare Administrative Contractors governing skin substitute coverage — including ApligrafApligrafAn FDA-approved living cell therapy and bioengineered skin substitute used in chronic wound care, including diabetic foot ulcers and venous leg ulcers.. The specific policy framework used to deny wound care in Michael Kissling's documented case.